Clinical Trials Logo

Clinical Trial Summary

International multi-center open-label randomized clinical trial of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) monotherapy compared to docetaxel as second-line therapy of patients with advanced inoperable or metastatic non-small cell lung cancer


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03288870
Study type Interventional
Source Biocad
Contact
Status Active, not recruiting
Phase Phase 2/Phase 3
Start date September 19, 2017
Completion date August 10, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03786692 - Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC Phase 2
Completed NCT04776083 - Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients Phase 3
Recruiting NCT05919264 - FOG-001 in Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT03042221 - Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
Recruiting NCT05274451 - A Study to Investigate LYL797 in Adults With Solid Tumors Phase 1
Recruiting NCT05372081 - Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer
Recruiting NCT03774732 - PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer Phase 3
Completed NCT03406468 - Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer Phase 2
Recruiting NCT04856176 - A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy Phase 2
Terminated NCT02967133 - A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer Phase 2
Completed NCT04710459 - Endobronchial Cryotherapy in Management of MEBO in Patients With Inoperable NSCLC N/A
Recruiting NCT03605602 - A Real World Study Based on NGS (TRUMPRWS)